Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Teva wins approval for generic Seroquel tablets
Final approval of this product is expected upon resolution of patent litigation. According to Teva, the brand product had annual sales of approximately $3.8 billion in the US
Final approval of this product is expected upon resolution of patent litigation. According to Teva, the brand product had annual sales of approximately $3.8 billion in the US
Under the terms of the definitive agreement, Thermage purchased Reliant for approximately $25 million in cash, 23.6 million shares of Thermage common stock, and the assumption of up
Mr Yockstick has broad management experience in executive and leadership positions across a wide range of commercial, operational, and quality functions, as well as being a leader and
Most recently, Mr Fust was executive vice president and CFO at Jazz Pharmaceuticals, which he joined in 2003. From 2002 until 2003, he was CFO at Perlegen Sciences.
Under the first tranche of the agreement, the company issued 2.6 million common shares at a price of $1.25 per common share. The common shares issued pursuant to
The proposal was communicated in a letter from Jeff Himawan, the chairman of MediciNova, to Zola Horovitz, the chairman of Avigen. The letter delivered to Dr Horovitz further
As part of its effort to restructure and consolidate operations, Neurogen is divesting certain non-core assets. Neurogen’s C5a patent estate and related assets were generated as part of
Dr Reddy’s will also market a generic version of the Clarinex 5mg tablet six months after the launch of the first generic version of that product. The agreements
The first step in this reorganization is the establishment of Covidien’s tax residency in Ireland in December 2008. Covidien shareholders then will be asked to vote in favor
The combined company will have a significant presence in over 60 countries and generated approximately $13.6 billion in revenues on a pro-forma basis for the 12 months ended